There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cogent Biosciences (COGT – Research Report) and Inozyme Pharma (INZY – Research Report) with bullish sentiments.
Cogent Biosciences (COGT)
Needham analyst Ami Fadia maintained a Buy rating on Cogent Biosciences today and set a price target of $18.00. The company’s shares closed last Tuesday at $7.76.
According to TipRanks.com, Fadia is a 4-star analyst with an average return of
Cogent Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $15.44, implying a 108.9% upside from current levels. In a report issued on April 29, LifeSci Capital also maintained a Buy rating on the stock with a $16.00 price target.
See the top stocks recommended by analysts >>
Inozyme Pharma (INZY)
In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Inozyme Pharma, with a price target of $23.00. The company’s shares closed last Tuesday at $4.60.
According to TipRanks.com, Stringer is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inozyme Pharma with a $17.00 average price target, which is a 254.9% upside from current levels. In a report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $14.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on COGT:
- Cogent Biosciences Reports First Quarter 2024 Financial Results
- Cogent Biosciences presents preclinical data of CNS-penetrant ErbB2 inhibitor
- Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
- Cogent Biosciences files to sell 31.2M shares of common stock for holders
